Samit Hirawat (Bristol Myers Squibb)

Af­ter bruis­ing re­jec­tion, blue­bird and Bris­tol My­ers Squibb land ide-cel pri­or­i­ty re­view. But will it mat­ter for the CVR?

With the clock all but up, the FDA ac­cept­ed and hand­ed pri­or­i­ty re­view to Bris­tol My­ers Squibb and blue­bird bio’s BC­MA CAR-T, keep­ing a nar­row …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.